BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 32666341)

  • 21. Expanding morphological and clinical aspects of hereditary leiomyomatosis and renal cell carcinoma (HLRCC): a case report in a patient with unusual morphology and clinical presentation.
    da Cunha IW; da Costa WH; Morini MA; Bezerra SM; Carraro DM; Torrezan GT; Formiga MNC; Guimaraes GC; Zequi SC; Soares FA
    Virchows Arch; 2018 Dec; 473(6):775-779. PubMed ID: 30171332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fumarate hydratase variant prevalence and manifestations among individuals receiving germline testing.
    Lu E; Hatchell KE; Nielsen SM; Esplin ED; Ouyang K; Nykamp K; Zavoshi S; Li S; Zhang L; Wilde BR; Christofk HR; Boutros PC; Shuch B
    Cancer; 2022 Feb; 128(4):675-684. PubMed ID: 34724198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel Fumarate Hydratase Mutation in Siblings With Early Onset Uterine Leiomyomas and Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome.
    Gunnala V; Pereira N; Irani M; Lilienthal D; Pirog EC; Soslow R; Caputo TA; Elias R; Kligman I; Rosenwaks Z
    Int J Gynecol Pathol; 2018 May; 37(3):256-261. PubMed ID: 28700432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma.
    Kopp RP; Stratton KL; Glogowski E; Schrader KA; Rau-Murthy R; Russo P; Coleman JA; Offit K
    Cancer; 2017 Jul; 123(13):2452-2458. PubMed ID: 28171700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers.
    Muller M; Ferlicot S; Guillaud-Bataille M; Le Teuff G; Genestie C; Deveaux S; Slama A; Poulalhon N; Escudier B; Albiges L; Soufir N; Avril MF; Gardie B; Saldana C; Allory Y; Gimenez-Roqueplo AP; Bressac-de Paillerets B; Richard S; Benusiglio PR
    Clin Genet; 2017 Dec; 92(6):606-615. PubMed ID: 28300276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma.
    Xu Y; Kong W; Cao M; Wang J; Wang Z; Zheng L; Wu X; Cheng R; He W; Yang B; Dong B; Pan J; Chen Y; Huang J; Jiang C; Zhai W; Li F; Chen R; Zhou X; Wu G; Geng X; Chen J; An H; Yuan Y; Xu T; Chen D; Lin D; Xu L; Huang K; Peng L; Yu Y; Tai S; Qi H; Luo K; Kang X; Wang H; Huang Y; Zhang J; Xue W
    Eur Urol; 2023 Feb; 83(2):163-172. PubMed ID: 35715365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hereditary leiomyomatosis and renal cell cancer (HLRCC): cutaneous and renal manifestations requiring a multidisciplinary team approach.
    Adams A; Sharpe KK; Peters P; Freeman M
    BMJ Case Rep; 2017 Apr; 2017():. PubMed ID: 28400389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of germline mutations in the fumarate hydratase gene and uterine fibroids in women with hereditary leiomyomatosis and renal cell cancer.
    Stewart L; Glenn GM; Stratton P; Goldstein AM; Merino MJ; Tucker MA; Linehan WM; Toro JR
    Arch Dermatol; 2008 Dec; 144(12):1584-92. PubMed ID: 19075141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hereditary leiomyomatosis and renal cell cancer (HLRCC): Case series and review of the literature.
    Yu Y; Zheng M; Zhu W; Zhao F; Guan B; Shen Q; Yang F; He Q; Li X
    Urol Oncol; 2021 Nov; 39(11):791.e9-791.e16. PubMed ID: 34462205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Uterine leiomyomas in hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome can be identified through distinct clinical characteristics and typical morphology.
    Uimari O; Ahtikoski A; Kämpjärvi K; Butzow R; Järvelä IY; Ryynänen M; Aaltonen LA; Vahteristo P; Kuismin O
    Acta Obstet Gynecol Scand; 2021 Nov; 100(11):2066-2075. PubMed ID: 34480341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fumarate hydratase FH c.1431_1433dupAAA (p.Lys477dup) variant is not associated with cancer including renal cell carcinoma.
    Zhang L; Walsh MF; Jairam S; Mandelker D; Zhong Y; Kemel Y; Chen YB; Musheyev D; Zehir A; Jayakumaran G; Brzostowski E; Birsoy O; Yang C; Li Y; Somar J; DeLair D; Pradhan N; Berger MF; Cadoo K; Carlo MI; Robson ME; Stadler ZK; Iacobuzio-Donahue CA; Joseph V; Offit K
    Hum Mutat; 2020 Jan; 41(1):103-109. PubMed ID: 31444830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights.
    Carlo MI; Hakimi AA; Stewart GD; Bratslavsky G; Brugarolas J; Chen YB; Linehan WM; Maher ER; Merino MJ; Offit K; Reuter VE; Shuch B; Coleman JA
    Eur Urol; 2019 Dec; 76(6):754-764. PubMed ID: 31326218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hereditary leiomyomatosis syndrome associated with renal cell carcinoma. A case report].
    González Ibáñez MV; Ruiz Cabezas L; Moreno Ontalba A; Rubio Fernández A; Mayoral Guisado C; Flores Barranquero M; Díaz Delgado M
    Rev Esp Patol; 2021; 54(3):193-196. PubMed ID: 34175032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Hereditary leiomyomatosis and renal cell cancer - HLRCC/multiple cutaneous and uterine leimomyomatosis - MCUL].
    Plevová P; Hladíková A; Tesařová M
    Klin Onkol; 2012; 25 Suppl():S55-8. PubMed ID: 22920208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fumarate Hydratase-deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome.
    Trpkov K; Hes O; Agaimy A; Bonert M; Martinek P; Magi-Galluzzi C; Kristiansen G; Lüders C; Nesi G; Compérat E; Sibony M; Berney DM; Mehra R; Brimo F; Hartmann A; Husain A; Frizzell N; Hills K; Maclean F; Srinivasan B; Gill AJ
    Am J Surg Pathol; 2016 Jul; 40(7):865-75. PubMed ID: 26900816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimation of the carrier frequency of fumarate hydratase alterations and implications for kidney cancer risk in hereditary leiomyomatosis and renal cancer.
    Shuch B; Li S; Risch H; Bindra RS; McGillivray PD; Gerstein M
    Cancer; 2020 Aug; 126(16):3657-3666. PubMed ID: 32413184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fumarate hydratase deficient renal cell carcinoma and fumarate hydratase deficient-like renal cell carcinoma: Morphologic comparative study of 23 genetically tested cases.
    Pivovarčíková K; Martínek P; Trpkov K; Alaghehbandan R; Magi-Galluzzi C; Mundo EC; Berney D; Suster S; Gill A; Rychlý B; Michalová K; Pitra T; Hora M; Michal M; Hes O
    Cesk Patol; 2019; 55(4):244-249. PubMed ID: 31842557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple cutaneous leiomyomas leading to discovery of novel splice mutation in the fumarate hydratase gene associated with HLRCC.
    Tan RYP; Walsh M; Howard A; Winship I
    Australas J Dermatol; 2017 Nov; 58(4):e246-e248. PubMed ID: 28266706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fumarate hydratase c.914T > C (p.Phe305Ser) is a pathogenic variant associated with hereditary leiomyomatosis and renal cell cancer syndrome.
    Breen KE; Carlo MI; Kemel Y; Maio A; Chen YB; Zhang L; Ceyhan-Birsoy O; Mandelker D
    Mol Genet Genomic Med; 2020 Aug; 8(8):e1293. PubMed ID: 32463173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A CASE OF FUMARATE HYDRATASE (FH)-DEFICIENT RENAL CELL CARCINOMA SUSPECTED OF HEREDITARY LEIOMYOMATOSIS RENAL CELL CARCINOMA].
    Hagiwara K; Urakami S; Sakaguchi K; Nagamoto S; Hayashida M; Oka S; Ogawa K; Okaneya T; Fujii T; Nagashima Y; Furuya M
    Nihon Hinyokika Gakkai Zasshi; 2021; 112(3):141-145. PubMed ID: 35858809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.